ArriVent BioPharma, Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
ArriVent announced publication of Phase 1b FURTHER trial results for firmonertinib in EGFR PACC-mutant NSCLC in Cancer Cell journal. The drug showed 43–68% confirmed overall response rates and 11.1–16.0 month median progression-free survival depending on dose (160 mg vs. 240 mg). ArriVent is continuing enrollment in the global Phase 3 ALPACCA trial comparing firmonertinib to osimertinib or afatinib in treatment-naïve EGFR PACC-mutant patients; PACC mutations represent ~12% of EGFR-mutant tumors with no current standard of care.
Why this rating
Peer-reviewed publication de-risks lead asset in large underserved indication; Phase 3 ongoing. Clinical-stage company; no revenue impact yet, but positive Phase 2 data with clear pathway to Phase 3 readout is material.
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.